News | June 08, 2010

Continuing Warfarin Therapy is Safe for Patients Undergoing Surgery

June 8, 2010 – New study findings prove continuing warfarin therapy during pacemaker or defibrillator implantation in patients with moderate to high thromboembolic risk is safe and cost-effective. According to research published in the June edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, cessation of warfarin with bridging anticoagulation resulted in a higher incidence of bleeding complications and a longer hospital stay. In addition, patients with temporarily interrupted anticoagulation suffered from a higher risk of transient ischemic attacks (TIA) than those who continued warfarin therapy.

The retrospective study evaluated 459 patients on warfarin therapy and underwent antiarrhythmic device surgery from April 2004 to September 2008 at Regions Hospital, a major teaching affiliate of the University of Minnesota Medical School. During the perioperative period, three groups matched in age, sex and risk factors for thromboembolism were observed. The patient groups included continued warfarin therapy (48 percent), cessation of warfarin with heparin bridging therapy (26 percent) and temporarily interrupted anticoagulation without bridging therapy (24 percent).

Overall study findings revealed patients who continued taking warfarin had a lower incidence of bleeding and a shorter hospital stay. The incidence of pocket hematoma formation was 16-fold in patients on heparin bridging therapy when compared to the patient group on continued warfarin therapy. Furthermore, patients who continued treatment on warfarin experienced no TIAs after the procedure while risks were reported for the patients with interrupted anticoagulation without heparin bridging therapy (3.5 percent) and the bridging therapy group (0.8 percent).

“Because of concerns about excessive bleeding and potential associated complications, many clinicians temporarily hold warfarin therapy with or without bridging therapy with heparin or enoxaparin in patients preparing to undergo device implantation,” said lead author Dennis W. Zhu, M.D., director of cardiac electrophysiology laboratory at Regions Hospital, St. Paul, Minn. and an associate professor of medicine at University of Minnesota. “While temporarily holding the use of warfarin with or without bridging therapy is a common and accepted practice in many cases, our study shows that continuing warfarin is in fact more beneficial to these patients from a safety and cost stand point.”

Current guidelines recommend stopping oral anticoagulation and starting bridging therapy with heparin or enoxaparin in patients at moderate to high risk for thromboembolic events. However, this study reveals that continuing warfarin therapy is more beneficial and may impact future decisions on patient treatment to improve overall outcomes.

For more information:

Related Content

SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts
Technology | Cardiovascular Surgery | February 01, 2019
Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) for a design...
Transplanting Pig Hearts Into Humans One Step Closer. A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

News | Cardiovascular Surgery | December 11, 2018
The scientific journal Nature recently published an article from Munich University Hospital which describes the long-...
Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Overlay Init